I specialize in developing genetic and cellular therapies for a wide range of diseases (Hematology, Rare diseases, Immunology, Oncology, Neurology, Dermatology, and Cardiovascular). During the past 24 years, I have built 6 startups from concept to advanced clinical trials in Israel and California. Currently, I offer consulting services to investors on complex biotechnological evaluations and to startup founders on building development plans and fundraising. At the same time, I am looking for the next idea that will excite me to build a new startup, preferably in the development of genetic therapies using advanced technologies.

My LinkedIn is:
https://www.linkedin.com/in/zoya-gluzman-poltorak-881679?utm_source=share&utm_campaign=share_via&utm_content=profile&utm_medium=ios_app

A short bio is below:

Dr. Gluzman-Poltorak, PHD MBA, has over 20 years of executive-level leadership experience in early development biotechnology companies, advancing several cell-, gene- and protein-based products from idea through pre-clinical into clinical development in multiple therapeutic areas (Hematology, Rare diseases, Immunology, Oncology, Neurology, Dermatology, and Cardiovascular). Recently she led Therapeutic Development as a CDO at SonoThera, Inc., South San Francisco, CA, a privately held company developing an ultrasound-guided nonviral gene therapy platform, building efficient in-house infrastructure and external collaborations and establishing preclinical, regulatory and clinical development plans. Prior to SonoThera, she pioneered the ASC Therapeutics at Applied Stem Cell to advance cutting-edge AAV genome editing, gene therapy and cell therapy products toward successful 2 IND submissions.


Prior to joining Applied Stem Cell, Dr. Gluzman-Poltorak worked at Neumedicines Inc., Pasadena, CA as a Senior Director of Development. She helmed pre-clinical and clinical development of NM-IL-12 (HemaMax) for Hematopoietic Syndrome of Acute Radiation Syndrome and other hematology and immuno-oncology indications, including proof-of-concept, toxicology, IND filing, complete efficacy program in NHPs, dose translation, FIH, Phase II and Phase III clinical studies. Prior to that she was a Chief Technology Officer at Gene Grafts Ltd. (2005-2009), and Angiogenesis Project Manager at MGVS Ltd. (2000-2004), developing innovative genetically modified cell therapy products to treat vascular, cardiologic, and neurologic disorders. She is a co-author of 11 patents and over 30 peer-reviewed publications.